BMO Capital Remains a Buy on Precision BioSciences (DTIL)

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Precision BioSciences (DTILResearch Report) today and set a price target of $7.00. The company’s shares opened today at $1.28.

Biliouris covers the Healthcare sector, focusing on stocks such as Beam Therapeutics, Legend Biotech, and Crispr Therapeutics AG. According to TipRanks, Biliouris has an average return of -9.6% and a 25.00% success rate on recommended stocks.

Precision BioSciences has an analyst consensus of Strong Buy, with a price target consensus of $7.75.

See today’s best-performing stocks on TipRanks >>

Based on Precision BioSciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $7.36 million and a GAAP net loss of $23.95 million. In comparison, last year the company earned a revenue of $24.04 million and had a GAAP net loss of $11.28 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company’s propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

Read More on DTIL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More